Merck预测2024年收入增长5%-7%, 尽管Keytruda专利于2028年到期。 Merck projects 5%-7% revenue increase in 2024, despite Keytruda patent expiration in 2028.

Merck在过去五年中实现了72%的回报率,这主要是由Keyturda免疫疗法驱动的,该疗法去年的销售额为263亿美元。 Merck has achieved a 72% return over the past five years, largely driven by its Keytruda immunotherapy, which generated $26.3 billion in sales last year. 然而,Keyturda的专利将于2028年到期,这引起了投资者的关切。 However, Keytruda's patent will expire by 2028, raising investor concerns. Merck预测2024年收入增长5%至7%, Merck projects a 5% to 7% revenue increase in 2024, with an earnings-per-share target of $7.94 to $8.04. 虽然该公司正在使其投资组合多样化,但是在寻找凯特鲁达后的增长方面仍然存在挑战。 While the company is diversifying its portfolio, the challenge remains to find growth post-Keytruda.

文章

The Motley Fool

Yahoo Finance

Biztoc

-- 显示更少 --

延伸阅读

相关故事